PMID- 27798164
OWN - NLM
STAT- MEDLINE
DCOM- 20170811
LR  - 20180124
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 197
IP  - 10
DP  - 2016 Nov 15
TI  - Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune
      Neuritis by Controlling Peripheral Nervous System Inflammation of Rats.
PG  - 3831-3840
AB  - Programmed death 1 (PD-1; CD279), a member of the CD28 family, is an inhibitory
      receptor on T cells and is responsible for T cell dysfunction in infectious
      diseases and cancers. The ligand for PD-1, programmed death ligand 1 (PD-L1; also
      known as B7-H1, CD274), is a member of the B7 family. The engagement of PD-1 with
      programmed death ligand can downregulate autoreactive T cells that participate in
      multiple autoimmune diseases. Experimental autoimmune neuritis (EAN) is an animal
      model of Guillain-Barre syndrome, and the pathogenesis of EAN is mediated
      principally through T cells and macrophages. In this study, we investigated the
      effects of PD-L1 in EAN rats. For preventative and therapeutic management, we
      administered PD-L1, which successfully decreased the severity of EAN; it
      alleviated the neurologic course of EAN, as well as inhibited the infiltration of
      inflammatory cells and demyelination of sciatic nerves. Our data revealed that
      PD-L1 treatment inhibited lymphocyte proliferation and altered T cell
      differentiation by inducing decreases in IFN-gamma(+)CD4(+) Th1 cells and
      IL-17(+)CD4(+) Th17 cells and increases in IL-4(+)CD4(+) Th2 cells and
      Foxp3(+)CD4(+) regulatory T cells. The expression levels of p-STAT3 and Foxp3
      were significantly different in PD-L1-treated groups compared with the control
      group. Additionally, PD-L1 regulated the expression of Foxp3 and p-STAT3 in EAN, 
      probably by inhibiting PI3K/AKT/mTOR signaling expression. In summary, PD-L1 is a
      potentially useful agent for the treatment of EAN because of its
      anti-inflammatory and neuroprotective effects.
CI  - Copyright (c) 2016 by The American Association of Immunologists, Inc.
FAU - Ding, Yanan
AU  - Ding Y
AD  - Department of Neurology, Tianjin Neurological Institute, Tianjin Medical
      University General Hospital, Tianjin 300052, China.
FAU - Han, Ranran
AU  - Han R
AD  - Department of Neurology, Tianjin Neurological Institute, Tianjin Medical
      University General Hospital, Tianjin 300052, China.
FAU - Jiang, Wei
AU  - Jiang W
AD  - Department of Neurology, Tianjin Neurological Institute, Tianjin Medical
      University General Hospital, Tianjin 300052, China.
FAU - Xiao, Jinting
AU  - Xiao J
AD  - Department of Neurology, Tianjin Neurological Institute, Tianjin Medical
      University General Hospital, Tianjin 300052, China.
FAU - Liu, Haijie
AU  - Liu H
AD  - Department of Neurology, Tianjin Neurological Institute, Tianjin Medical
      University General Hospital, Tianjin 300052, China.
FAU - Chen, Xiuju
AU  - Chen X
AD  - Department of Neurology, Tianjin Neurological Institute, Tianjin Medical
      University General Hospital, Tianjin 300052, China.
FAU - Li, Xiaowen
AU  - Li X
AD  - Department of Neurology, Tianjin Neurological Institute, Tianjin Medical
      University General Hospital, Tianjin 300052, China.
FAU - Hao, Junwei
AU  - Hao J
AD  - Department of Neurology, Tianjin Neurological Institute, Tianjin Medical
      University General Hospital, Tianjin 300052, China hjw@tijmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161017
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Interleukin-17)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - AIM
SB  - IM
MH  - Animals
MH  - B7-H1 Antigen/metabolism/*pharmacology
MH  - CD4-Positive T-Lymphocytes/drug effects/immunology
MH  - Cell Differentiation/drug effects
MH  - Cell Proliferation/drug effects
MH  - Demyelinating Diseases/prevention & control
MH  - Disease Models, Animal
MH  - Gene Expression Regulation
MH  - Guillain-Barre Syndrome/immunology
MH  - Interferon-gamma/drug effects
MH  - Interleukin-17/immunology
MH  - Interleukin-4/immunology
MH  - Lymphocyte Activation
MH  - Neuritis, Autoimmune, Experimental/*immunology/physiopathology/*therapy
MH  - Peripheral Nervous System/*immunology
MH  - Rats
MH  - Sciatic Nerve/drug effects
MH  - T-Lymphocytes, Regulatory
MH  - Th17 Cells/drug effects/immunology
MH  - Th2 Cells
EDAT- 2016/11/01 06:00
MHDA- 2017/08/12 06:00
CRDT- 2016/11/06 06:00
PHST- 2016/06/28 00:00 [received]
PHST- 2016/09/20 00:00 [accepted]
PHST- 2016/11/06 06:00 [entrez]
PHST- 2016/11/01 06:00 [pubmed]
PHST- 2017/08/12 06:00 [medline]
AID - jimmunol.1601083 [pii]
AID - 10.4049/jimmunol.1601083 [doi]
PST - ppublish
SO  - J Immunol. 2016 Nov 15;197(10):3831-3840. doi: 10.4049/jimmunol.1601083. Epub
      2016 Oct 17.